Immunotherapy in Advanced Urothelial Cancer- Matthew Campbell

Matthew Campbell, MD, provides an overview of metastatic urothelial cancer (mUC) and PD-1/PD-L1 blockade as the new standard in second line therapy.  In addition, Dr. Campbell discuss the ongoing and future exploration in UC.

Biography:
Matthew Campbell Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Additional reading:
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

A phase II study of atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients 

Systemic Immunotherapy Bladder Cancer.. Get Ready
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe